跳至主要内容
临床试验/DRKS00022190
DRKS00022190招募中未知

Individualized Metacognitive Therapy (MCT+) for patients with schizophrenia - 5 year follow-up

niversitätsklinikum Hamburg-EppendorfKlinik und Poliklinik für Psychiatrie und Psychotherapie0 个研究点目标入组 329 人开始时间: 2020年7月9日最近更新:
适应症

试验速览

阶段
未知
状态
招募中
发起方
入组人数
329

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomized controlled study
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
All

入选标准

  • This trial does not aim to recruit any new subjects, but rather to contact and reassess previously included study participants.
  • 1) Schizophrenic spectrum disorder (ICD-F2x, verified using the MINI)
  • 2) Ability to consent

排除标准

  • 1) Intelligence: IQ < 70, measured with a vocabulary test (WST)
  • 2) Rating for uncooperative behaviour and hostility = 5 on the PANSS scale (range: 1-7; G8, P7)
  • 3) Acute suicidality
  • 4) Current substance and alcohol dependence, except tobacco (i.e. abstinence < 6 months; substance and alcohol abuse are tolerated)
  • 5) neurological or medical disease that may cause the psychotic symptoms
  • 6) Participation in MCT+ within the last 12 months
  • 7) Insufficient knowledge of German for participation in MCT+
  • 8) insufficient testability

研究者

发起方
niversitätsklinikum Hamburg-EppendorfKlinik und Poliklinik für Psychiatrie und Psychotherapie

相似试验

Individualized Metacognitive Therapy (MCT+) for... | 临床试验